Post Date November, 16 2024
Because one end of the urethral mucosa is stratified squamous epithelium, while the middle of the urethra is stratified or pseudostratified columnar epithelium, and the moving epithelium is close to the inner mouth of the urethra, the urethral administration is easier to absorb than the penis glans skin, because the latter is composed of keratinized stratified squamous epithelium, and the drug is not easy to absorb. In addition, when the drug is absorbed by the urethral epithelium, it can communicate with the cavernous vein of the penis through the cavernous vein of the urethra to make the drug pass through the urethral mucosa and finally be absorbed by the smooth muscle of the cavernous body of the penis. Of course, its dose is far greater than cavernous injection.
MUSE is the abbreviation of Medicated Urethral System for Erection, and is a special urethral drug delivery tool for PGE.
Specific methods: add PGE1. After the absorption of the urethral mucosa, apply the front row urine once, and then insert the MUSE device into the urethra through the external orifice of the urethra for about 33 cm, push and press the MUSE device button, so that the PGE1 small pill can be squeezed into the middle of the urethra, pull out the MUSE device, and gently massage the penis PGE1 with your hand. When massaging the penis, stand and walk for about 10-15 minutes. If effective, the penis erection can last for about 30-60 minutes. In order to strengthen the clinical effect of transurethral administration, It is recommended to set a rubber narrowing ring at the root of the penis. PGE1 doses are 125ug, 250ug, 500ug and 1000ug, which can be selected according to individual differences.
Effect: According to the clinical observation results of a group of 1511 cases, the total efficiency of MUSE (PGE) is 66%. 12% of patients use 125ug. In addition, 17%, 30% and 41% of patients need to use 250ug, 500ug and 1000ug. The etiology of the observed cases in this group is classified as: vascular dysfunction (ED) accounting for 28.7%, diabetes accounting for 20.6%, surgery and trauma accounting for 29.6%, and the other 21% are other reasons. MUSE has no difference in the efficacy of erectile dysfunction for various reasons. According to the clinical research results of a double-blind placebo group, the efficiency of MUSE (PGE1) was 65%, while that of placebo group was only 18%. 6% of the treatment group effectively used MUSE for 10 times and had satisfactory sexual life for 7 times, which was independent of the user's age.
Side effects: The main side effect of urethral administration is urethral distension and pain, accounting for about 30%, but most of them still adhere to medication. With the gradual proficiency of application technology, the incidence of urethral pain can be reduced to about 10%. A small number of patients use MUSE to slightly injure the urethra, causing blood in urine or bleeding. Very few patients cause general discomfort such as dizziness.
Although PGE1.80% of the urethral drugs were absorbed after 10 minutes, some spouses still complained of vaginal discomfort or itching. Of course, this may be related to the residue of PGE1 in semen. The spouse's husband uses it during childbirth. MUSE (PGE1) wears condoms to prevent adverse effects on offspring.
Recent studies suggest that if PGE1 is mixed with alpha receptor blocker such as Prazosin for urethral administration, it can improve the clinical effect and reduce the occurrence of adverse reactions.
